Recently, the Ministry of Commerce and the National Development and Reform Commission released the "Action Plan for Stabilizing Foreign Investment in 2025" (hereinafter referred to as the "Plan"), which clearly proposes to increase support for foreign investment and promote the sustained growth and optimization of foreign investment in China. The Plan specifically lists support measures for the biopharmaceutical field. During an interview with Xinhua News Agency, Shi Wang, President of Sanofi Greater China, highly praised this plan, stating that it demonstrates China's firm determination to promote high-level opening-up and deepen high-quality development, as well as its strategic vision of deeply participating in global innovation cooperation. It not only helps foreign-funded enterprises to improve their localization layout and global supply chain resilience, but also provides strong institutional guarantees for the deep collaboration and ecological co construction between multinational pharmaceutical companies and local partners. China is Sanofi's second largest strategic market, with over 40 years of continuous investment. Sanofi is a multinational pharmaceutical and health enterprise headquartered in Paris, France, and opened an office in China in 1982. As one of the first multinational companies to enter China at the beginning of the reform and opening up, Sanofi has brought over 60 innovative drugs and vaccines to the Chinese market over the past 40 years, covering 7 of the top 10 deadly diseases in China. Shi Wang said that biopharmaceuticals, as a key field for China's high-level opening up to the outside world and enhancing people's well-being, will accelerate the construction of a full chain collaborative innovation industry ecology through a series of policy measures such as phased pilot projects. The introduction of this action plan will not only provide stronger institutional guarantees for the development of multinational enterprises in China, inject a stimulant for their sustained investment in China, but also better support Sanofi's innovation capacity building in the local area, promote international cooperation and industrial upgrading of biomedicine. Shi Wang stated that thanks to China's high-level opening-up policy and strong support for regulating the business environment for foreign investment, Sanofi has continuously increased its investment in China, building an end-to-end value chain from local research and development, production, and operation. Currently, it has 12 diversified offices, 3 production bases, and 4 major research and development bases. China has also become Sanofi's second largest market in the world. In December 2024, Sanofi announced that it will invest approximately 1 billion euros in China to build a new insulin production base in Beijing. This will be Sanofi's fourth production and supply base in China, not only setting a record for the company's largest single investment in China, but also an important measure for Sanofi to strengthen its industrial chain layout after a total investment of about 1.7 billion yuan in Yizhuang, Beijing in 1995 and a capital increase of 500 million yuan in 2022, demonstrating its commitment and confidence in deepening its long-term development in China. The newly built Beijing insulin production base, together with the Beijing production base to be expanded in 2023, as well as the production bases in Shenzhen and Hangzhou, will form a high-quality production capacity guarantee for Sanofi in China, enhance the flexibility of the supply chain in China, and more efficiently meet the growing demand of diabetes patients. After nearly 30 years of development, Sanofi Beijing production base has become Sanofi's largest insulin injection production base in the Asia Pacific region, with products covering diabetes, cardiovascular, medical and tumor fields. Previously, Sanofi also signed a Sino French strategic cooperation agreement with the Shenzhen Municipal Government, creating China's first international vaccine innovation center - the Greater Bay Area International Vaccine Innovation Center, and establishing strategic partnerships with Chinese companies such as Shanghai Pharmaceuticals to explore innovative models in the commercialization of mature products. In the field of new drugs, as of the end of 2024, Sanofi has established cooperative relationships with nearly 300 hospitals and over 1100 clinical research centers in China to promote the development of new drugs. Currently, there are about 100 clinical trials underway or planned, of which 15 have been approved for early clinical trials, covering multiple fields such as immunology, oncology, neurology, and rare diseases. In addition, Sanofi has multiple important drugs, including Yilaike for transplantation What are the key strategies in the field of cardiovascular disease And the use of daptomidine in atopic dermatitis? All of them have been included in the new national medical insurance catalog for 2024. China's biomedicine has made rapid progress. Sanofi is willing to cooperate deeply with local innovation Shiwang said that it expects to accelerate the landing of global cutting-edge pharmaceutical innovation achievements in China through the implementation of the policy of stabilizing foreign investment, and further deepen the construction of innovation, research and development and production supply chain in the Chinese market, so as to make positive contributions to the high-quality development of Chinese manufacturing. As one of the world's largest healthcare markets, China has the most complex and diverse immune and healthcare needs, as well as unique vitality, massive scale, and thriving technological innovation, which are key factors in promoting the formation of new quality productivity in the field of biomedicine. Shi Wang said that thanks to decades of positive policy support from the government, China's biomedical innovation system has developed rapidly in recent years, and the speed of local research and development is increasingly synchronized with the global market. A number of Chinese innovative pharmaceutical enterprises have made breakthroughs in the global scope, demonstrating excellent research and development strength and certain international competitiveness, especially in the fields of cancer, autoimmune diseases, metabolic diseases, etc., some local innovative products have entered the global market, and have been recognized by international regulators. Sanofi is actively collaborating with local innovative pharmaceutical and technology companies, and attempting to accelerate the pace of innovation and deeply integrate into the local ecosystem through research investment. Immunology science is a very clear strategic focus for Sanofi, and we hope to continue to cooperate with local enterprises in this field's innovative forces. At present, Sanofi is utilizing artificial intelligence (AI) technology, including target discovery engines, drug design modeling, and digital patient populations, to develop highly promising first of its kind drugs and optimal drug pipelines, in order to accelerate research progress and help China prevent or modify chronic and infectious diseases, including respiratory diseases such as asthma, chronic obstructive pulmonary disease, respiratory syncytial virus, and influenza; Skin diseases such as atopic dermatitis, psoriasis, and acne; Autoimmune diseases, such as multiple sclerosis, type 1 diabetes, inflammatory bowel disease, etc. Sanofi has successively established strategic partnerships with local enterprises such as Shangyao Holdings, Kaihui Fund, Tianjing Biotechnology, Jixing Pharmaceutical, and Baitu Biotechnology. From multiple dimensions such as innovative business models, R&D innovation cooperation, and digital innovation ecology, Sanofi has joined hands with local forces to jointly build an innovative medical ecosystem. Shi Wang stated that Sanofi firmly believes that there will be more opportunities in the future to engage in meaningful cooperation with innovative Chinese pharmaceutical companies and explore the possibility of various partnership relationships. (New Society)